Prevention of nocturnal elevation of intraocular pressure by gene transfer of dominant-negative RhoA in rats

JAMA Ophthalmology

Volumn 133, Issue 2, 2015, Pages 182-190

  Borrás, Teresa ^a   Buie, Lakisha K ^b   Spiga, Maria Grazia ^b   Carabana, Juan ^b  

^a UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

RHOA GUANINE NUCLEOTIDE BINDING PROTEIN; DNA; RECOMBINANT PROTEIN;

ADENO ASSOCIATED VIRUS 2; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DOMINANT GENE; DOMINANT NEGATIVE RHOA GENE; DRUG EFFICACY; GENE TRANSFER; HUMAN; HUMAN CELL; IMMUNE RESPONSE GENE; IN VITRO STUDY; INTRAOCULAR PRESSURE ABNORMALITY; MALE; NOCTURNAL ELEVATED INTRAOCULAR PRESSURE; NONHUMAN; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROMOTER REGION; RAT; REAL TIME POLYMERASE CHAIN REACTION; SINGLE DRUG DOSE; TONOMETRY; TRABECULAR MESHWORK; VIRAL GENE DELIVERY SYSTEM; VIRAL GENE THERAPY; VIRUS PARTICLE; ADULT; ANIMAL; CELL CULTURE; CIRCADIAN RHYTHM; DISEASE MODEL; DRUG EFFECTS; GENETICS; INJECTION; INTRAOCULAR PRESSURE; MUTATION; OCULAR HYPERTENSION; PATHOPHYSIOLOGY; PHYSIOLOGY; WISTAR RAT;

ADULT; ANIMALS; CELLS, CULTURED; CIRCADIAN RHYTHM; DISEASE MODELS, ANIMAL; DNA; GENE TRANSFER TECHNIQUES; HUMANS; INJECTIONS; INTRAOCULAR PRESSURE; MALE; MUTATION; OCULAR HYPERTENSION; RATS; RATS, WISTAR; RECOMBINANT PROTEINS; RHOA GTP-BINDING PROTEIN; TRABECULAR MESHWORK;

EID: 84922938368     PISSN: 21686165     EISSN: 21686173     Source Type: Journal    
DOI: 10.1001/jamaophthalmol.2014.4747     Document Type: Article

References (41)

1. Caprioli J, Varma R. Intraocular pressure: modulation as treatment for glaucoma. Am J Ophthalmol. 2011;152(3):340-344.e2. doi:10.1016/j.ajo.2011.05.029.
2. Drance SM. The significance of the diurnal tension variations in normal and glaucomatous eyes. Arch Ophthalmol. 1960;64(4):494-501.
3. Liu JH, Kripke DF, Hoffman RE, et al. Nocturnal elevation of intraocular pressure in young adults. Invest Ophthalmol Vis Sci. 1998;39(13):2707-2712.
4. Liu JH, Zhang X, Kripke DF, Weinreb RN. Twenty-four-hour intraocular pressure pattern associated with early glaucomatous changes. Invest Ophthalmol Vis Sci. 2003;44(4):1586-1590.
5. Moore CG, Johnson EC, Morrison JC. Circadian rhythm of intraocular pressure in the rat. Curr Eye Res. 1996;15(2):185-191.
6. Zhao M, Hejkal JJ, Camras CB, Toris CB. Aqueous humor dynamics during the day and night in juvenile and adult rabbits. Invest Ophthalmol Vis Sci. 2010;51(6):3145-3151.
7. Giannetto C, Piccione G, Giudice E. Daytime profile of the intraocular pressure and tear production in normal dog. Vet Ophthalmol. 2009;12 (5):302-305.
8. Sigle KJ, Camaño-Garcia G, Carriquiry AL, Betts DM, Kuehn MH, McLellan GJ. The effect of dorzolamide 2% on circadian intraocular pressure in cats with primary congenital glaucoma. Vet Ophthalmol. 2011;14(suppl 1):48-53.
9. Liu JH, Kripke DF, Twa MD, et al. Twenty-four-hour pattern of intraocular pressure in the aging population. Invest Ophthalmol Vis Sci. 1999;40(12):2912-2917.
10. Nau CB, Malihi M, McLaren JW, Hodge DO, Sit AJ. Circadian variation of aqueous humor dynamics in older healthy adults. Invest Ophthalmol Vis Sci. 2013;54(12):7623-7629.
11. Liu H, Fan S, Gulati V, et al. Aqueous humor dynamics during the day and night in healthy mature volunteers. Arch Ophthalmol. 2011;129(3): 269-275.
12. Lee YR, Kook MS, Joe SG, et al. Circadian (24-hour) pattern of intraocular pressure and visual field damage in eyes with normal-tension glaucoma. Invest Ophthalmol Vis Sci. 2012;53(2): 881-887.
13. Lichter PR, Musch DC, Gillespie BW, et al; CIGTS Study Group. Interim clinical outcomes in the Collaborative Initial Glaucoma Treatment Study comparing initial treatment randomized to medications or surgery. Ophthalmology. 2001;108 (11):1943-1953.
14. Schwartz K, Budenz D. Current management of glaucoma. Curr Opin Ophthalmol. 2004;15(2):119-126.
15. Liu JH, Medeiros FA, Slight JR, Weinreb RN. Diurnal and nocturnal effects of brimonidine monotherapy on intraocular pressure. Ophthalmology. 2010;117(11):2075-2079.
16. Liu JH, Kripke DF, Weinreb RN. Comparison of the nocturnal effects of once-daily timolol and latanoprost on intraocular pressure. Am J Ophthalmol. 2004;138(3):389-395.
17. Orzalesi N, Rossetti L, Invernizzi T, Bottoli A, Autelitano A. Effect of timolol, latanoprost, and dorzolamide on circadian IOP in glaucoma or ocular hypertension. Invest Ophthalmol Vis Sci. 2000;41 (9):2566-2573.
18. Rowland JM, Potter DE, Reiter RJ. Circadian rhythm in intraocular pressure: a rabbit model. Curr Eye Res. 1981;1(3):169-173.
19. Lawson CD, Burridge K. The on-off relationship of Rho and Rac during integrin-mediated adhesion and cell migration. Small GTPases. 2014;5(1):e27958. doi:10.4161/sgtp.27958.
20. Uehata M, Ishizaki T, Satoh H, et al. Calcium sensitization of smooth muscle mediated by a Rho-associated protein kinase in hypertension. Nature. 1997;389(6654):990-994.
21. Honjo M, Tanihara H, Inatani M, et al. Effects of Rho-associated protein kinase inhibitor, Y-27632, on intraocular pressure and aqueous humor dynamics in the rabbit eye [abstract]. Invest Ophthalmol Vis Sci. 2000;41:S510.
22. Thieme H, Nuskovski M, Nass JU, Pleyer U, Strauss O, Wiederholt M. Mediation of calcium-independent contraction in trabecular meshwork through protein kinase C and rho-A. Invest Ophthalmol Vis Sci. 2000;41(13):4240-4246.
23. Honjo M, Tanihara H, Inatani M, et al. Effects of Rho-associated protein kinase inhibitor Y-27632 on intraocular pressure and outflow facility. Invest Ophthalmol Vis Sci. 2001;42(1):137-144.
24. Rao PV, Deng PF, Kumar J, Epstein DL. Modulation of aqueous humor outflow facility by the Rho kinase-specific inhibitor Y-27632. Invest Ophthalmol Vis Sci. 2001;42(5):1029-1037.
25. Kameda T, Inoue T, Inatani M, et al. The effect of Rho-associated protein kinase inhibitor on monkey Schlemm's canal endothelial cells. Invest Ophthalmol Vis Sci. 2012;53(6):3092-3103.
26. Tanihara H, Inatani M, Honjo M, Tokushige H, Azuma J, Araie M. Intraocular pressure-lowering effects and safety of topical administration of a selective ROCK inhibitor, SNJ-1656, in healthy volunteers. Arch Ophthalmol. 2008;126(3):309-315.
27. Inoue T, Tanihara H. Rho-associated kinase inhibitors: a novel glaucoma therapy. Prog Retin Eye Res. 2013;37:1-12.
28. Vittitow JL, Garg R, Rowlette LL, Epstein DL, O'Brien ET, Borrás T. Gene transfer of dominant-negative RhoA increases outflow facility in perfused human anterior segment cultures. Mol Vis. 2002;8:32-44.
29. Liu X, Hu Y, Filla MS, et al. The effect of C3 transgene expression on actin and cellular adhesions in cultured human trabecular meshwork cells and on outflow facility in organ cultured monkey eyes. Mol Vis. 2005;11:1112-1121.
30. Buie LK, Rasmussen CA, Porterfield EC, et al. Self-complementary AAV virus (scAAV) safe and long-term gene transfer in the trabecular meshwork of living rats and monkeys. Invest Ophthalmol Vis Sci. 2010;51(1):236-248.
31. Acland GM, Aguirre GD, Ray J, et al. Gene therapy restores vision in a canine model of childhood blindness. Nat Genet. 2001;28(1):92-95.
32. Comes N, Buie LK, Borrás T. Evidence for a role of angiopoietin-like 7 (ANGPTL7) in extracellular matrix formation of the human trabecular meshwork: implications for glaucoma. Genes Cells. 2011;16(2):243-259.
33. Buie LK, Karim MZ, Smith MH, Borrás T. Development of a model of elevated intraocular pressure in rats by gene transfer of bone morphogenetic protein 2. Invest Ophthalmol Vis Sci. 2013;54(8):5441-5455.
34. Khosravi-Far R, Solski PA, Clark GJ, Kinch MS, Der CJ. Activation of Rac1, RhoA, and mitogen-activated protein kinases is required for Ras transformation. Mol Cell Biol. 1995;15(11):6443-6453.
35. McCarty DM, Monahan PE, Samulski RJ. Self-complementary recombinant adeno-associated virus (scAAV) vectors promote efficient transduction independently of DNA synthesis. Gene Ther. 2001;8(16):1248-1254.
36. Xiao X, Li J, Samulski RJ. Production of high-titer recombinant adeno-associated virus vectors in the absence of helper adenovirus. J Virol. 1998;72(3):2224-2232.
37. Massie B, Couture F, Lamoureux L, et al. Inducible overexpression of a toxic protein by an adenovirus vector with a tetracycline-regulatable expression cassette. J Virol. 1998;72(3):2289-2296.
38. Zode GS, Kuehn MH, Nishimura DY, et al. Reduction of ER stress via a chemical chaperone prevents disease phenotypes in a mouse model of primary open angle glaucoma. J Clin Invest. 2011;121 (9):3542-3553.
39. Maeda A, Tsujiya S, Higashide T, et al. Circadian intraocular pressure rhythm is generated by clock genes. Invest Ophthalmol Vis Sci. 2006;47(9): 4050-4052.
40. Hamamura K, Swarnkar G, Tanjung N, et al. RhoA-mediated signaling in mechanotransduction of osteoblasts. Connect Tissue Res. 2012;53(5):398-406.
41. Testa F, Maguire AM, Rossi S, et al. Three-year follow-up after unilateral subretinal delivery of adeno-associated virus in patients with Leber congenital amaurosis type 2. Ophthalmology. 2013; 120(6):1283-1291.